These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 23677114)
1. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. Chang AL; Atwood SX; Tartar DM; Oro AE JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114 [No Abstract] [Full Text] [Related]
2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Wolfe CM; Green WH; Cognetta AB; Hatfield HK Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146 [No Abstract] [Full Text] [Related]
3. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904 [TBL] [Abstract][Full Text] [Related]
4. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient. Kieny A; Kremer V; Scheidecker S; Lipsker D Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423 [No Abstract] [Full Text] [Related]
5. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome. Ally MS; Wysong A; Tang JY; Aasi S Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843 [No Abstract] [Full Text] [Related]
6. Histologic changes in basal cell carcinoma after treatment with vismodegib. Aldabagh B; Yu J; Perkocha LA; Arron S Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864 [No Abstract] [Full Text] [Related]
7. Vismodegib in advanced basal-cell carcinoma. Henkin RI N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271 [No Abstract] [Full Text] [Related]
8. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224 [TBL] [Abstract][Full Text] [Related]
9. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors. Zhu GA; Li AS; Chang AL JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076 [TBL] [Abstract][Full Text] [Related]
10. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. Tauber G; Pavlovsky L; Fenig E; Hodak E J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385 [TBL] [Abstract][Full Text] [Related]
11. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps. Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175 [No Abstract] [Full Text] [Related]
12. Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome. Lukowiak TM; Cahn B; Samie F; Leffell DJ; Oro A; Kibbi N; Kheterpal M; Babakoohi S; Khushalani NI; Stephenson A; Ma MS; Shi VJ; Ahmed A; Koza E; Haq M; Yi MD; Nadir U; Yoo S; Brieva JC; Lucas J; Haber R; Alam M Arch Dermatol Res; 2024 Jul; 316(7):453. PubMed ID: 38967654 [No Abstract] [Full Text] [Related]
13. Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition. Jussila AR; Haensel D; Gaddam S; Oro AE J Invest Dermatol; 2024 Jun; 144(6):1368-1377.e6. PubMed ID: 38157930 [TBL] [Abstract][Full Text] [Related]
14. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. Lear JT N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909 [No Abstract] [Full Text] [Related]
15. Efficacy, tolerability, and quality of life evaluation in six patients affected by Gorlin-Goltz syndrome and treated with vismodegib 150 mg/die: a retrospective monocentric cohort analysis. Scotti B; Melotti B; Baraldi C; Venturi F; Lambertini M; Dika E Ital J Dermatol Venerol; 2024 Aug; 159(4):453-454. PubMed ID: 39069844 [No Abstract] [Full Text] [Related]
16. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097 [TBL] [Abstract][Full Text] [Related]
17. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome. Yang X; Dinehart SM JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945 [No Abstract] [Full Text] [Related]
18. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series. Wong C; Poblete-Lopez C; Vidimos A J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372 [No Abstract] [Full Text] [Related]
19. Severe Rheumatoid Arthritis Developing in Conjunction with Gorlin Syndrome. Scott JF; Bordeaux JS J Rheumatol; 2016 Jul; 43(7):1447-9. PubMed ID: 27371652 [No Abstract] [Full Text] [Related]
20. Complete response of a locally advanced basosquamous carcinoma with vismodegib treatment. Sahuquillo-Torralba A; Llavador-Ros M; Caballero-Daroqui J; Botella-Estrada R Indian J Dermatol Venereol Leprol; 2019; 85(5):549-552. PubMed ID: 31389370 [No Abstract] [Full Text] [Related] [Next] [New Search]